On November 9, the FDA approved dasatinib (Sprycel®) for the treatment of children with chronic myelogenous leukemia (CML) whose cancer cells express the Philadelphia chromosome and whose disease is in a relatively early stage, known as the chronic phase.
http://ift.tt/2As3IwE
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου